You are here

Article Text

Article menu
Download PDFPDF
Evidence-based medicine
Oral prednisolone reduced exacerbation of symptoms in children with virally induced lower airway disease

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Csonka P, Kaila M, Laippala P, et al. Oral prednisolone in the acute management of children age 6 to 35 months with viral respiratory infection-induced lower airway disease: a randomized, placebo-controlled trial. J Pediatr2003;143:725–30.
    OpenUrlCrossRefPubMedWeb of Science



    Q In children 6–35 months of age with virally induced lower airway disease (VILAD), is oral prednisolone (OP) more effective than placebo for reducing exacerbation of symptoms, hospital length of stay, and duration of symptoms?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Paediatrics ★★★★★☆☆ Respirology ★★★★★☆☆ Emergency medicine ★★★★★★☆

    METHODS

    Embedded ImageDesign:

    randomised placebo controlled trial.

    Embedded ImageAllocation:

    concealed.*

    Embedded ImageBlinding:

    blinded (participants and healthcare providers).*

    Embedded ImageFollow up period:

    14 days.

    Embedded ImageSetting:

    a university hospital in Tampere, Finland.

    Embedded ImagePatients:

    248 children 6–35 years of age who presented to a paediatric emergency department with VILAD (acute tachypnoea, wheezing, or use of accessory respiratory muscles). Exclusion critera included asthma, inspiratory stridor, epiglottitis, foreign body aspiration, and chronic pulmonary diseases. 230 children (mean age 17 …

    View Full Text

    Footnotes

    Footnotes